title: Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives.
abstract: After the press release in Lancet (October 18, 1995) of increased risks for adverse vascular events in users of pills containing desogestrel and gestodene the total sales of oral contraceptives dropped over a two-month period by 17%, while sales of the only desogestrel brand available (Marvelon) dropped by over 70% in Norway. From sales, we can estimate that more than 45,000 women either changed from Marvelon to a second or first-generation brand or stopped using OCs. In total, more than 25,000 women discontinued OC use in Norway during November and December of 1995. Abortion data from one Norwegian county, representing 6-7% of the Norwegian population, show no statistically significant changes in the total number of induced abortions from the first quarter of 1996 as compared with that of the first quarter in preceding years. However, abortion rates that had been steadily decreasing from 1992 through 1995 in women 24 years old or younger, were promptly interrupted by a significant 36% increase during the first quarter of 1996. Most of the additional cases were found among single, childless students. The observed increased abortion rate among younger women is most probably linked to changes in contraceptive use during the pill scare of the late October through December of 1995, during which time these women conceived.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital of Trondheim, Norway.
authors.forename: F E
authors.initials: FE
authors.lastname: Skjeldestad
mesh_terms: D000028:Abortion, Induced / Q000191:economics / Q000706:statistics & numerical data*; D000293:Adolescent; D000328:Adult; D003267:Contraception / Q000523:psychology / Q000706:statistics & numerical data*; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D017135:Desogestrel / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D005260:Female; D006801:Humans; D015994:Incidence; D009664:Norway / Q000453:epidemiology; D011247:Pregnancy; D012307:Risk Factors; D012847:Single Person / Q000706:statistics & numerical data; D013334:Students / Q000706:statistics & numerical data; D013924:Thrombophlebitis / Q000139:chemically induced / Q000453:epidemiology
chemical_list: D003280:Contraceptives, Oral, Synthetic; D017135:Desogestrel